Long-term consequences of osteoporosis therapy with denosumab
ABSTRACT Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Sociedade Brasileira de Endocrinologia e Metabologia
2022-12-01
|
| Serie: | Archives of Endocrinology and Metabolism |
| Soggetti: | |
| Accesso online: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000500717&tlng=en |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|